Salarius Pharmaceuticals Renames to Decoy Therapeutics, Ticker DCOY

Salarius Pharmaceuticals will change its corporate name to Decoy Therapeutics and its common shares will trade on the Nasdaq Capital Market under the ticker symbol DCOY effective as of commencement of trading on January 8. These changes reflect the Company's focus on developing novel peptide-conjugate therapeutics through its proprietary platform that reduces the complexity of drug development and manufacturing. "Changing our corporate name is another step in our transformation to developing the next generation of peptide-conjugate therapeutics, with an initial emphasis on high-priority viral and oncology targets," said Rick Pierce, CEO. "With an AI-enabled discovery engine, a lead antiviral program of interest to global health stakeholders and a tightly focused 2026 plan, we are positioned to advance our first program into the clinic, expand our pipeline and create long-term value for patients and shareholders." These changes do not affect the total number of shares outstanding, shareholders' rights, the CUSIP number or the transfer agent, nor do they impact the Company's operations or leadership, which includes Decoy's senior management team and Salarius' finance team. The Company's priorities for 2026 include: Advancing lead antiviral programs toward regulatory readiness; Expanding discovery and preclinical validation across multiple platforms; Leveraging AI-enabled computational infrastructure to accelerate candidate selection; Pursuing strategic collaborations with big pharma, technology leaders and academic institutions; Strengthening the Company's capital structure and expanding investor visibility.